NephroPlus Reports Strong H1FY27 Performance and International Expansion
Nephrocare Health Services Ltd · Investor Presentation · 03 Nov 2026, 11:57 pm
NephroPlus Reports Strong H1FY27 Performance and International Expansion Nephrocare Health Services delivered strong H1FY27 results, with revenue growing 23.6% YoY to ₹585.2 crore, driven by a 12.6% YoY rise in treatments to 21.01 lakh and a 9.7% YoY increase in revenue per treatment to ₹2,785. Adjusted EBITDA rose 15.3% YoY to ₹134.4 crore (23.0% margin), while adjusted PAT surged 34.7% YoY to ₹76.1 crore. The global clinic network expanded to 570 centres across six countries, with international operations contributing 47% of Q2FY27 revenue following entries into Kazakhstan and Saudi Arabia alongside Philippines expansion.
Original exchange filing (PDF)
More announcements from Nephrocare Health Services Ltd
- We hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith. · 17 Nov 2026
- Pursuant to Reg 30 of SEBI Listing Regulations, 2015, we hereby inform that the Company has approved allotment of 3,42,130 equity shares of Rs. 2/- each, pursuant to the exercise of stock .... · 17 Nov 2026
- Please find enclosed herewith Transcripts for the Investors Earnings call held on November 4, 2026. · 12 Nov 2026
- Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith. · 12 Nov 2026
- In Continuation to our letter dated October 21, 2026 please find enclosed link of the audio recording of the Investors'' Conference Call held on November 04, 2026 on the Unaudited Standalone .... · 04 Nov 2026
- Please find attached monitoring agency report for the quarter ended September 30, 2026. · 04 Nov 2026
- Press release on Unaudited standalone and consolidated financial results for quarter and half year ended September 30, 2026. · 03 Nov 2026
- Outcome of the Board meeting held on November 3, 2026 for considering and approving the financial results for the period ended September 30, 2026. · 03 Nov 2026
